Press Room

IFPAC 2023

Start
Sunday, June 04, 2023 - 00:00
End
Wednesday, June 07, 2023 - 00:00
Location: Maryland, USA

Hovione is present at the International Forum Process Analytical Technology (IFPAC), a forum that brings the latest trends and real-life applications in the fields of Quality by Design, Process Analytical Technology, Emerging Technologies, Quality Metrics, Continuous Manufacturing and Process Control applications for the pharmaceutical industry, biotechnology, generic, chemical and related industries.

 

HOVIONE PRESENTATIONS

Hovione experts share their knowledge at IFPAC® - 37th International Forum Process Analytical Technology
June 4-7, 2023 | North Bethesda, Maryland (Washington D.C.)

 

June 6: Grand Ballroom G | 4:50 PM - 5:15 PM
Part of session: Recent Developments to Realizing Continuous Manufacturing
Presentation Title: Use of Statistical Process Control to drive process improvements in continuous manufacturing
Primary presenter: Fernando Barros

 

June 7: Grand Ballroom C | 7:50 AM - 12:00 PM
Session: Defining Incentives and Business Cases for PAT - Defining the Boundaries between Batch & Continuous Manufacturing
Chair: Anthony Tantuccio

 

June 7: Glen Echo Conference Room | 11:10 AM - 11:35 AM
Part of session: Enhanced Analytical Approaches & Modeling for Process Optimization
Presentation Title: A template for investigating NIR spectroscopy-based deviations
Primary presenter: Fernando Barros

 

June 7: White Flint Amphitheatre | 1:05 PM - 5:40 PM
Part of session: Continued Process Verification (CPV) - Practices, Challenges and Opportunities
Presentation Title: Enhance Spray Drying CPV using MVDA
Primary presenter: Tiago Porfirio

 

One approach to enhancing Continued process verification (CPV) is through the use of multivariate data analysis (MVDA), which allows for the identification of correlations and patterns between process parameters and product quality attributes. MVDA involves the analysis of multiple variables simultaneously, allowing for a comprehensive understanding of the process and its impact on product quality. By analyzing data from multiple sources, including automated control systems and quality control testing, MVDA can help identify the critical process parameters (CPPs) and critical quality attributes (CQAs) that are most strongly correlated with product quality. This approach can significantly improve process efficiency and product quality while reducing the risk of product failure, reprocessing and rework. Moreover, MVDA provide insights into potential causes for process deviations, facilitating the development of corrective actions. This proactive approach to CPV helps to ensure that the process remains within established control limits, minimizing the risk of non-compliance. This work will show how the integration of MVDA into CPV in a spray drying process can significantly enhance process control and product quality by leveraging multivariate data analysis.
 

 

 

Meet our experts. Let’s discuss your project together.

 

 

Find more about IFPAC.

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026